Medacta Receives FDA Clearance for the Lateralized Glenosphere

EQS Group-Media / 02.09.2020 / 19:00 Media Release Medacta Receives FDA Clearance for the Lateralized Glenosphere CASTEL SAN PIETRO, 02 September 2020 - Medacta announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Lateralized Glenosphere. This implant, which received the CE marking in 2019, further expands the Medacta offering for shoulder arthroplasty, broadening the range of options for reverse shoulder replacement surgery. The Lateralized Glenosphere features a more lateralized center of rotation compared to the standard glenosphere currently offered with the Medacta Shoulder System. The potential benefits of a more lateralized construct include an improved range of motion and a reduced risk of scapular notching. The Medacta Shoulder System is a modular solution that includes a wide range of sizes, adjustable offset and innovative configurations for both the anatomic and reverse shoulder arthroplasty. It is compatible with the CT-based MyShoulder 3D preoperative planning solution, offering patient-specific humeral and glenoid guides. Earlier in 2020, the Medacta Shoulder System expanded with the introduction of the Long Humeral Diaphysis. This new option, together with the Lateralized Glenosphere, makes the Medacta Shoulder System increasingly complete and innovative. For more information on the Medacta Shoulder System and Medacta's shoulder arthroplasty solutions, visit www.medacta.us.com/US/medacta-shoulder-system-us.Contact Medacta International SA Gianluca Olgiati Senior Director Global Marketing Phone: +41 91 696 60 60media@medacta.ch About Medacta Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated MySolutions technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures. Issuer: Medacta Group SA Key word(s): Research/Technology End of Corporate News Language: English Company: Medacta Group SA Strada Regina 6874 Castel San Pietro Switzerland Phone: +41 91 696 6060 E-mail: info@medacta.ch,investor.relations@medacta.ch Internet: www.medacta.com ISIN: CH0468525222 Listed: SIX Swiss Exchange EQS News ID: 1126883   End of News EQS Group Media 1126883  02.09.2020